Healthcare provider profile · identity verified

Scott David Morgan, MD

Allopathic & Osteopathic Physicians|Family Medicine · MERCER, PA · NPI 1467419689

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Scott David Morgan, MD received $122.41 in general payments during 2025 across 7 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 30.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 7 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Synthroid by this doctor in 2024.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$122.41

7 reported records · 6 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$37.42	30.6%	2	2025
Exact Sciences Corporation	Unresolved — no canonical attribution shown	$18.77	15.3%	1	2025
Inspire Medical Systems, Inc.	Unresolved — no canonical attribution shown	$18.68	15.3%	1	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$16.30	13.3%	1	2025
Xeris Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$16.02	13.1%	1	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$15.22	12.4%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$122.41	7

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$37.42	2	2025
Source payment records 2025-08-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.65 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.77 · Open Payments source
Cologuard Collection Kit Normalized: cologuard collection kit	Device	Exact Sciences Corporation	$18.77	1	2025
Source payment records 2025-04-02 · Exact Sciences Corporation · $18.77 · Open Payments source
INSPIRE Normalized: inspire	Device	Inspire Medical Systems, Inc.	$18.68	1	2025
Source payment records 2025-04-10 · Inspire Medical Systems, Inc. · $18.68 · Open Payments source
ELIQUIS Normalized: eliquis	Drug	E.R. Squibb & Sons, L.L.C.	$16.30	1	2025
Source payment records 2025-08-14 · E.R. Squibb & Sons, L.L.C. · $16.30 · Open Payments source
GVOKE HYPOPEN Normalized: gvoke hypopen	Drug	Xeris Pharmaceuticals, Inc.	$16.02	1	2025
Source payment records 2025-05-20 · Xeris Pharmaceuticals, Inc. · $16.02 · Open Payments source
QULIPTA Normalized: qulipta	Drug	ABBVIE INC.	$15.22	1	2025
Source payment records 2025-09-10 · ABBVIE INC. · $15.22 · Open Payments source
UBRELVY Normalized: ubrelvy	Drug	ABBVIE INC.	$15.22	1	2025
Source payment records 2025-09-10 · ABBVIE INC. · $15.22 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	238	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	43	14
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	238	30

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Omeprazole	Omeprazole	677	97
Levothyroxine Sodium	Levothyroxine Sodium	594	101
Gabapentin	Gabapentin	573	93
Atorvastatin Calcium	Atorvastatin Calcium	550	118
Pantoprazole Sodium	Pantoprazole Sodium	535	104
Amlodipine Besylate	Amlodipine Besylate	501	100
Losartan Potassium	Losartan Potassium	390	77
Albuterol Sulfate Hfa	Albuterol Sulfate	321	69
Potassium Chloride	Potassium Chloride	267	47
Tamsulosin Hcl	Tamsulosin Hcl	255	64
Eliquis	Apixaban	238	30
Lisinopril	Lisinopril	234	58
Montelukast Sodium	Montelukast Sodium	234	31
Furosemide	Furosemide	231	50
Simvastatin	Simvastatin	231	45
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	228	30
Metformin Hcl	Metformin Hcl	228	50
Azithromycin	Azithromycin	210	144
Prednisone	Prednisone	186	83
Metoprolol Tartrate	Metoprolol Tartrate	179	42
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	177	43
Metoprolol Succinate	Metoprolol Succinate	173	31
Rosuvastatin Calcium	Rosuvastatin Calcium	172	38
Sertraline Hcl	Sertraline Hcl	169	34
Meloxicam	Meloxicam	167	46
Ozempic	Semaglutide	164	24
Famotidine	Famotidine	162	26
Hydrochlorothiazide	Hydrochlorothiazide	161	36
Buspirone Hcl	Buspirone Hcl	156	32
Duloxetine Hcl	Duloxetine Hcl	154	28
Alprazolam	Alprazolam	152	24
Esomeprazole Magnesium	Esomeprazole Magnesium	152	23
Allopurinol	Allopurinol	149	27
Tramadol Hcl	Tramadol Hcl	138	35
Celecoxib	Celecoxib	135	36
Pravastatin Sodium	Pravastatin Sodium	132	27
Escitalopram Oxalate	Escitalopram Oxalate	124	25
Pioglitazone Hcl	Pioglitazone Hcl	124	24
Glipizide Er	Glipizide	123	31
Mounjaro	Tirzepatide	121	20
Citalopram Hbr	Citalopram Hydrobromide	118	23
Topiramate	Topiramate	118	suppressed
Mirtazapine	Mirtazapine	116	27
Clopidogrel	Clopidogrel Bisulfate	115	25
Fluticasone Propionate	Fluticasone Propionate	109	31
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	107	76
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	104	19
Xarelto	Rivaroxaban	103	16
Levetiracetam	Levetiracetam	102	suppressed
Atenolol	Atenolol	91	14
Ibuprofen	Ibuprofen	91	28
Doxycycline Hyclate	Doxycycline Hyclate	90	58
Lorazepam	Lorazepam	89	29
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	88	11
Trulicity	Dulaglutide	88	16
Ventolin Hfa	Albuterol Sulfate	88	17
Carvedilol	Carvedilol	87	19
Finasteride	Finasteride	86	17
Warfarin Sodium	Warfarin Sodium	84	15
Trazodone Hcl	Trazodone Hcl	82	17
Metformin Hcl Er	Metformin Hcl	81	20
Glipizide	Glipizide	79	19
Ondansetron Hcl	Ondansetron Hcl	78	30
Ropinirole Hcl	Ropinirole Hcl	75	11
Oxybutynin Chloride	Oxybutynin Chloride	73	suppressed
Oxycodone Hcl	Oxycodone Hcl	73	14
Torsemide	Torsemide	73	15
Venlafaxine Hcl Er	Venlafaxine Hcl	73	17
Fenofibrate	Fenofibrate Nanocrystallized	72	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	69	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	69	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	68	14
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	67	40
Amoxicillin	Amoxicillin	66	50
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	66	18
Baclofen	Baclofen	65	suppressed
Valsartan	Valsartan	65	20
Aripiprazole	Aripiprazole	62	12
Sumatriptan Succinate	Sumatriptan Succinate	60	12
Diclofenac Sodium	Diclofenac Sodium	59	15
Glipizide-Metformin	Glipizide/Metformin Hcl	58	12
Oxybutynin Chloride Er	Oxybutynin Chloride	56	suppressed
Clonazepam	Clonazepam	55	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	54	14
Lamotrigine	Lamotrigine	53	suppressed
Megestrol Acetate	Megestrol Acetate	53	suppressed
Spironolactone	Spironolactone	52	12
Myrbetriq	Mirabegron	51	suppressed
Solifenacin Succinate	Solifenacin Succinate	51	suppressed
Paroxetine Hcl	Paroxetine Hcl	50	11
Donepezil Hcl	Donepezil Hcl	49	11
Fluoxetine Hcl	Fluoxetine Hcl	49	suppressed
Risperidone	Risperidone	48	suppressed
Bupropion Xl	Bupropion Hcl	47	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	47	11
Jardiance	Empagliflozin	44	suppressed
Nabumetone	Nabumetone	43	14
Synthroid	Levothyroxine Sodium	43	14
Fluconazole	Fluconazole	42	19
Methocarbamol	Methocarbamol	42	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	42	suppressed
Nifedipine Er	Nifedipine	41	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	39	30
Sucralfate	Sucralfate	39	suppressed
Ibandronate Sodium	Ibandronate Sodium	38	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	38	suppressed
Clonidine Hcl	Clonidine Hcl	37	suppressed
Divalproex Sodium Er	Divalproex Sodium	37	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	37	20
Pregabalin	Pregabalin	36	suppressed
Mometasone Furoate	Mometasone Furoate	35	18
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	33	suppressed
Cephalexin	Cephalexin	33	23
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	33	22
Methylprednisolone	Methylprednisolone	32	25
Ciprofloxacin Hcl	Ciprofloxacin Hcl	31	24
Novolog Flexpen	Insulin Aspart	31	suppressed
Propranolol Hcl	Propranolol Hcl	30	suppressed
Carbamazepine	Carbamazepine	29	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Calcitonin-Salmon	Calcitonin,salmon,synthetic	28	suppressed
Fenofibrate	Fenofibrate,micronized	28	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	28	suppressed
Bupropion Hcl Sr	Bupropion Hcl	27	suppressed
Morphine Sulfate	Morphine Sulfate	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Naproxen	Naproxen	26	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Fenofibrate	Fenofibrate	25	suppressed
Mupirocin	Mupirocin	25	16
Valacyclovir	Valacyclovir Hcl	25	12
Lacosamide	Lacosamide	24	suppressed
Meclizine Hcl	Meclizine Hcl	24	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	23	suppressed
Rybelsus	Semaglutide	23	suppressed
Verapamil Er	Verapamil Hcl	23	suppressed
Azelastine Hcl	Azelastine Hcl	22	suppressed
Benazepril Hcl	Benazepril Hcl	22	suppressed
Enalapril Maleate	Enalapril Maleate	22	suppressed
Ketoconazole	Ketoconazole	22	15
Ondansetron Odt	Ondansetron	22	suppressed
Repaglinide	Repaglinide	22	suppressed
Testosterone Cypionate	Testosterone Cypionate	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	21	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	21	20
Benztropine Mesylate	Benztropine Mesylate	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Terbinafine Hcl	Terbinafine Hcl	20	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	20	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	19	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	19	suppressed
Klor-Con M20	Potassium Chloride	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Ibu	Ibuprofen	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Methimazole	Methimazole	18	suppressed
Bethanechol Chloride	Bethanechol Chloride	17	suppressed
Doxepin Hcl	Doxepin Hcl	17	suppressed
Ketorolac Tromethamine	Ketorolac Tromethamine	17	suppressed
Glimepiride	Glimepiride	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	suppressed
Invega Sustenna	Paliperidone Palmitate	15	suppressed
Nystatin	Nystatin	15	suppressed
Tiotropium Bromide	Tiotropium Bromide	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	14	suppressed
Cefdinir	Cefdinir	14	12
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	14	suppressed
Levofloxacin	Levofloxacin	14	13
Olanzapine	Olanzapine	14	suppressed
Spiriva Handihaler	Tiotropium Bromide	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Digoxin	Digoxin	13	suppressed
Epinephrine	Epinephrine	13	suppressed
Fesoterodine Fumarate Er	Fesoterodine Fumarate	13	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	13	suppressed
Mesalamine	Mesalamine	13	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	13	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	13	suppressed
Tenormin	Atenolol	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Clotrimazole	Clotrimazole	12	suppressed
Colchicine	Colchicine	12	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	12	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Forteo	Teriparatide	12	suppressed
Haloperidol	Haloperidol	12	suppressed
Humalog	Insulin Lispro	12	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Methadone Hcl	Methadone Hcl	12	suppressed
Novolin N	Insulin Nph Human Isophane	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Desmopressin Acetate	Desmopressin Acetate	11	suppressed
Dilantin	Phenytoin Sodium Extended	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Lyrica	Pregabalin	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Trifluoperazine Hcl	Trifluoperazine Hcl	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed
Verapamil Hcl	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$122.41 · 7 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	CAPLYTA, Cologuard Collection Kit, ELIQUIS, GVOKE HYPOPEN, INSPIRE, QULIPTA, UBRELVY	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error